

AROA BIOSURGERY H1 RESULTS WEBINAR & INVESTOR EVENT

Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX, AROA' or the 'Company') will hold an investor event on Tuesday, 25 November 2025 at 8:30am AEDT in Sydney, with both in person and online attendance options available.

Attendees will hear from AROA's leadership team on the H1 FY26 results and commercial outlook. The session will also include an update from commercial partner, TelaBio, along with presentations from two leading surgeons, sharing their experience and clinical outcomes using Myriad™.

The event offers investors the opportunity to hear directly from management and clinicians on AROA's product innovation, clinical efficacy of AROA ECM™ technology, and the Company's growth trajectory.

Further details on the Investor event, including registrations options, are provided below.

08.30am - 10.40am: H1 FY26 Financial Results and Guest Presentations – hybrid event

Time	Session	Speakers
0830 AEDT	H1 FY26 Financial Results	AROA CEO Brian Ward & CFO James Agnew, attending in person
0910 AEDT	TelaBio Business Update.	TelaBio CEO Anthony Koblisch & TelaBio President, Jeff Blizzard, attending online
0940 AEDT	Emerging evidence in trauma procedures from AROA's ongoing MASTRR clinical study	Dr. Alison Smith, Assistant Professor of Clinical Surgery, Louisiana State University, attending online
1010 AEDT	Early experience using Myriad Matrix to treat burns in Australia	Dr. Jason Brown, Director of The Professor Stuart Pegg Adult Burn Centre, Brisbane, attending in person

10.40am - 12.40pm: Round Table Discussions – in person only event

Following H1 FY26 Results and presentations from guests, in person attendees are invited to participate in rotating round table discussions with AROA management personnel on the following topics.

Session	Speakers
Commercial Strategy	Brian Ward, CEO
Symphony Product Strategy and Reimbursement Update	Mike Linnell, Global Product Manager & Director International Marketing
ENIVO™ Commercialisation Update	Isaac Mason, VP Product Development
Ovitex Product Portfolio Overview	James Agnew, CFO

For personal use only

Register to attend

- **Online** via the following link:
https://us02web.zoom.us/webinar/register/WN_Cuz-dbZNTNerA65M6Q851g
- **In person:** please RSVP to investor@aroa.com at your earliest convenience. Due to limited capacity, registration in advance is required.

Questions

Questions can be submitted in advance to investor@aroa.com or live during the event.

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

About Aroa Biosurgery:

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Over 7 million AROA products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio, Inc. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroa.com

Contacts

investor@aroa.com

For personal use only